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studyquestion: Does inhibition of dimethylarginine dimethylaminohydrolase (DDAH) increase the sensitivity of trophoblasts to TRAIL-
induced apoptosis?
summaryanswer: Inhibition of DDAH1, but not DDAH2, increases the sensitivity of trophoblasts to TRAIL-induced apoptosis.
what is knownalready: Successful humanpregnancy is dependentonadequate trophoblast invasionand remodellingof thematernal
spiral arteries. Increased trophoblast apoptosis is seen in pregnancies complicated by pre-eclampsia. The mechanism underlying this increase is
unknown.Wehavepreviously shown thatnitric oxide (NO) is involved in regulating trophoblastmotility and invasion, andhave alsodemonstrated
an important role for NO in regulating trophoblast sensitivity to apoptotic stimuli. DDAH is an enzyme that metabolizes asymmetric dimethy-
larginine (ADMA), an endogenous inhibitor of NO synthesis, previously shown to be elevated in the plasma of pre-eclamptic mothers.
study design, size, duration: This study used the human extravillous trophoblast-derived cell line SGHPL-4 cells. All experiments
were performed at least three times.
participants/materials, setting, methods: The effect ofDDAHon trophoblast apoptosis was examined using siRNA and
time-lapsemicroscopy.Changes in the expression ofDDAHwere followed by PCR andwestern blot analysis. Receptor expressionwas followed
by ﬂow cytometry.
main results and the role of chance: Inhibiting theexpressionofDDAH1, but notDDAH2, resulted in a signiﬁcant increase in
the sensitivityof the EVTcell line SGHPL-4 to tumournecrosis factor related apoptosis inducing ligand (TRAIL) inducedapoptosis (P, 0.01). This
response could be mimicked by the addition of Asymmetric Dimethylarginine (ADMA), an endogenous inhibitor of NO synthesis and the sub-
strate for both isoforms of DDAH.We further showed that this increased sensitivity to apoptosis is accompanied by a signiﬁcant increase in the
expression of TRAIL receptor 2 (TR2; P, 0.05) but not TRAIL receptor 1 (TR1).
limitations, reasons for caution: This study was performed only in vitro using a well characterized trophoblast cell line,
SGHPL-4, derived from ﬁrst trimester extravillous trophoblasts.
wider implications of the findings: This study provides new insight into the role of the DDAH/ADMA pathway in the regu-
lation of trophoblast function. Both dysregulation of DDAH and the accumulation of ADMA have been associated with the development of pre-
eclampsia. This is the ﬁrst study to implicate theDDAH/ADMApathwayas amechanism thatmight underlie thepoor trophoblast invasion seen in
this common pregnancy disorder.
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Introduction
In normal healthy pregnancies extravillous trophoblast (EVT) cells of the
placenta invade the decidua where they interact with and ultimately
replace the vascular smoothmuscle and endothelial cells of thematernal
spiral arteries. This is a well-orchestrated process dependent on the ﬁne
balance between EVT cell proliferation and cell death mediated through
apoptotic mechanisms (Smith et al., 1997b; Huppertz et al., 2006). Any
disturbance in this balance can result in shallow EVT invasion and poor
spiral artery remodelling, as seen in pre-eclampsia (PE) and fetal
growth restriction (FGR) (DiFederico et al., 1999; Kadyrov et al.,
2001). Early onset PE is a signiﬁcant cause ofmaternal and neonatal mor-
bidity andmortality affecting up to5%of all births. Babies bornof PEpreg-
nancies are at increased risk of developing cardiovascular and metabolic
diseases later in life (Davis et al., 2012). Themechanisms responsible for
the poor trophoblast invasion and inadequate remodelling have yet to be
determined although a reducedcapacity to invade and/or increased sen-
sitivity to apoptotic stimuli may play a signiﬁcant role.
A number of agonists trigger apoptosis, including tumour necrosis
factor-a (TNFa), TNF-related apoptosis inducing ligand (TRAIL) and
Fas ligand (FasL), which interact with members of the TNF death recep-
tor family.TRAILexists eitheras type IImembraneboundhomotrimeror
as a soluble fragment (sTRAIL) produced following proteolytic cleavage.
Both the membrane bound and the soluble forms of TRAIL can rapidly
induce apoptosis. TRAIL interacts with ﬁve receptors, TRAIL R1 (TR1)
and TRAIL R2 (TR2), also known as DR4 and DR5 respectively, two
decoy receptors (DcR4 andDcR5), and a soluble receptor called osteo-
protegerin (Sheridan et al., 1997; Emery et al., 1998). EVT express both
TRAIL and its receptors, however TRAIL is also expressed by other cells
at the maternal fetal interface including decidual stromal and immune
cells early in gestation (Phillips et al., 1999). Although EVT are relatively
resistant to apoptotic stimulation, we have previously shown that inhib-
ition of NO synthesis can increase their sensitivity to members of the
TNF superfamily, including TRAIL (Dash et al., 2007).
Nitric oxide (NO) is an important signallingmolecule that acts inmany
tissues to regulate a diverse range of physiological processes, most
notably: vasodilation, inﬂammation and immune function. NO is synthe-
sized from l-arginine through the catalytic activity of the NO synthase
(NOS) family of enzymes. NO has been implicated in many aspects of
both normal pregnancies and those complicated by PE through its
action as a vasodilator (Yallampalli and Garﬁeld, 1993; Buhimschi et al.,
1995) and there is increased interest in NO as a possible therapeutic
target for PE and FGR. We have previously demonstrated the involve-
mentof endogenously producedNO in trophoblastmotility and invasion
and have found that NO is important in regulating the sensitivity of
trophoblast to apoptotic stimuli (Cartwright et al., 1999; Dash et al.,
2003a,b).
NO synthesis can be regulated in a number of ways including gene ex-
pression, enzymatic activation or changes in substrate or cofactor avail-
ability. In addition NO synthesis can be competitively inhibited by
methylated analogues of arginine including asymmetric dimethylarginine
(ADMA), which is formed following the hydrolysis of methylated pro-
teins. Dimethylarginine dimethylaminohydrolase (DDAH) is an enzyme
that catabolises the hydrolysis of ADMA to citrulline and dimethylamine
(Leiper andVallance, 1999). In early pregnancy the circulating concentra-
tion of ADMA falls, which could result in an increase in NO production
and a decrease in vascular resistance and maternal blood pressure
(Holden et al., 1998). Throughout gestation the circulating concentration
ofADMArises, however, in PE pregnancies the rise is signiﬁcantly greater
(Holden et al., 1998; Ellis et al., 2001).
In this studywe tested the hypothesis that changes in the expression of
DDAH, akey regulatorofNOsynthesis, could lead to changes in the sen-
sitivity of an EVT cell line to TRAIL-induced apoptosis.
Materials andMethods
Cell culture
SGHPL-4 cells, derived from primary human ﬁrst trimester extravillous tro-
phoblasts, have been used extensively as amodel of extravillous trophoblasts
(Choy and Manyonda, 1998; Cartwright et al., 2002; Dash et al., 2003a) and
in particular studies investigating the role of NO in apoptosis where they
respond in a similar manner to primary extravillous trophoblasts (Dash
et al., 2003a,b, 2005; Whitley et al., 2007). SGHPL-4 cells were cultured in
Hams F-10media supplemented with 2 mM L-glutamine, 100 units/ml peni-
cillin, 0.1 mg/ml streptomycin and 10% (v/v) fetal calf serum (FCS).
Inhibition of DDAH expression using siRNA
SGHPL-4 cells were treated with Dharmacon siGENOME SMARTpool
siRNA siRNA constructs as per the manufacturer’s instructions (Little Chal-
fontUK). Speciﬁcally, SGHPL-4 cellswere seeded in 6well plates in 10% (v/v)
FCS in Hams F10 containing glutamine and penicillin and streptomycin as
detailed above. When conﬂuent the medium was replaced with serum-free
Hams-F10 without antibiotics and cultured overnight. Cells were then
treated for 24 h with 20 nM siRNA and 4 ml Dharmafect in serum and anti-
biotic free media, and incubated for a further 48 h in Hams-F10 containing
10% FCS (v/v). A control treatment with a non-targeting siRNA was
carried out concurrently, to account for any changes resulting from transfec-
tion alone. The siRNA sequences were as follows; DDAH1: GCAGCAAA
CUGUAUAUAUC/GAAGGAGGUUGACAUGAU/CAACAAAGGGCA
CGUCUUG/CAGAUGGGUUUGCAUUUGAA; DDAH2: GGAAAUAG
GAGACGAGAAC/UGACAGAUCACCCAUAUGC/GCACUGACGUU
CUCUUCAC/GAUCUGGCCAAAGCUCAAA; and non-targeting pool
#2:UAAGGCUAUGAAGAGAUAC/AUGUAUUGGCCUGUAUUAG/A
UGAACGU GAAUUGCUCAA/UGGUUUACAUGUCGACUAA.
RNA isolation
RNA was isolated using Qiagen RNeasy RNA mini kit, as per the manufac-
turer’s instructions (QIAGEN, West Sussex, UK).
SYBR green quantitative RT–PCR analysis
RNAwas reverse transcribed using Bioline cDNA synthesis kit according to
manufacturer’s instructions (Tetro cDNA kit, components: Tetro RTase,
oligo (dT)18, random hexamer primers, ultra-pure dNTPs, RNase Inhibitor,
BIOLINE, London,UK). 40 ng cDNAwasused induplicate samples for quan-
titative RT–PCR using Power SYBR green Master Mix (Applied Biosystems,
LifeTechnologies,Carlsbad,CA,USA)asper themanufacturer’s instructions
using the following sequence speciﬁc primers: 18S: ACA-CGT-TCC-ACC-
TCA-TCC-TC and CTT-TGC-CAT-CAC-TGC-CAT-TA, DDAH1: CCA-
GTT-TAG-GCT-TAC-CAG-CA and TGC-AAT-GTA-GAA-GAG-GCA-
CA, DDAH2: CAG-GGG-TAG-TAT-AGG-AAG-TAG and TAT-TGA-
GGC-TCT-CTC-CCA-ACT-AC. Q-PCR was carried out using a Bio-Rad
CFX96 Real-Time PCR Detection System (Bio- Rad, Hemel Hempstead,
UK). The PCR ampliﬁcation protocol was as follows: Step 1: 958C for 10
min (enzyme activation), Step 2: 958C for 15 s (denaturation), Step 3: 558C
for 60 s (data collection), Step 4: Repeat step 2 and 3 (40 cycles) and
Step 5: Melt curve: 55–958C at 0.58C increments for 5 s each; the cycle
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threshold was ,25. Primers were purchased from Primer Design (South-
ampton, UK) or Eurogentec (Southampton, UK) with primer efﬁciencies of
.90% (DDAH1: 98%, 18S: 96%). Expression of analysed geneswas normal-
ized to RNA loading for each sample using the 18S ribosomal RNA as an in-
ternal standard and fold changes were calculated using the delta cT method;
results were normalized to a calibrator sample to control for intra-assay
variability.
Western blot analysis
Cells were collected and lysed by scraping into RIPA buffer containing the
protease inhibitors phenylmethylsulfonyl ﬂuoride (1 mM), sodium orthova-
nadate (1 mM) and aprotinin (60 mg/ml). Proteins were resolved by SDS
PAGE in 10% gels, and transferred to PVDF membranes. Membranes were
subsequently blocked in 5%w/v skimmedmilk powder dissolved in Tris buf-
fered saline containing 0.1% v/v Tween-20 (Sigma-Aldrich, Dorset, UK)
(TBS-T) for 1 h. Membranes were incubated overnight, at 48C in goat anti
Human DDAH1 antibody (1:1000 in 5% w/v skimmed milk powder/
TBS-T) (Torondel et al., 2010) and subsequently in secondary rabbit anti-
goat HRP (Sigma Dorset UK) for 1 h at room temperature (1:10 000 in in
5% w/v skimmed milk powder/TBS-T). Detection was performed using
ELC plus (Millipore, Watford, UK). Blots were subsequently blocked and
re-probed with a mouse anti tubulin antibody (0.15 mg/ml; Abcam,
Cambridge, UK, ab11323). Western blots were scanned and the integrated
intensity of each band was determined using Image J (Schneider et al., 2012).
The Western blots shown are representative of at least three experiments
and the results shown are relative to the intensity of tubulin.
Determination of apoptosis
Cells were treated with siRNA as above or for 6 h with 10, 100 or 200 mM
ADMA-2HCl (Sigma Dorset, UK). TRAIL was then added at a ﬁnal concen-
tration of 500 ng/ml (Keogh et al., 2007; Agostinis et al., 2012) and the cells
were subject to time-lapse microscopy, as previously described (Dash et al.,
2003b). Apoptotic morphologywas characterized by cytoplasmic shrinkage,
nuclear condensation, a phase bright appearance, and formation of mem-
brane blebbing and blistering (Whitley et al., 2007). Cells were visualized
throughout the experiment using an Olympus IX71 inverted phase-contrast
microscope (Olympus, Japan) with a motorized stage (Prior scientiﬁc, Cam-
bridge,UK) andcooledCCDcamera (HamamatsuPhotonics,Hertfordshire,
UK, model C4742-95) enclosed in a humidiﬁed chamber at constant 378C
(Solent Scientiﬁc, Segensworth, UK). Images were captured every 15 min
over 24 h using Image Pro Plus software (media Cybernetics, Bethesda,
USA). Two ﬁelds of view were captured at 10× magniﬁcation, at each
time point, for each treatment group and 20 cells were analysed blind in
each ﬁeld of view. The time frame at which apoptotic morphology was ﬁrst
observed in 20 randomly selected cells, in each ﬁeld of view was recorded.
TRAIL receptor expression
Cell mono-layers were washed with PBS and detached with Versene (sup-
plied as a 1× solution of 0.2 g/l ethylenediaminetetraacetic acid, Life Tech-
nologies, Carlsbad, CA, USA) at 378C. Following centrifugation at 500×g,
the cells were washed in PBS and re-suspended in FACS buffer (PBS, 0.5%
w/v BSA, 0.1% NaN3). The Fc receptors were blocked by the incubation
of 5 × 105 cells per tube with 1 mg human IgG at 48C for 30 min. For the
Figure1 The effect of siRNA transfection on the expression of DDAH1 and 2 in SGHPL-4 cells. The effect of transfecting SGHPL-4 cells with a targeted
siRNA on the expression of DDAH1 (A) or DDAH2 (B) mRNAwas followed by qPCR. The speciﬁcity of the siRNAwas conﬁrmed by transfection of a
non-targeting siRNA control construct. Protein knockdown of DDAH 1 by western blot analysis is demonstrated in a representative western blot for
DDAH1 and Tubulin (C) as well as in the combined densitometric data (D). The data are shown as mean + SEM from at least three independent experi-
ments, *P, 0.05, **P, 0.01 compared with non-targeting control.
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detection and quantiﬁcation of TRAIL R1 and R2, 2.5 × 105 cells were incu-
batedwithantibodieseither,TRAILR1(PEconjugated, FAB347P,25 mg/ml)or
R2 (Alexa 488 conjugated, FAB6311G, 50 mg/ml), the appropriate IgG
control, mouse IgG1- PE conjugated (IC002P, 25 mg/ml) or mouse IgG2B
– Alexa 488 conjugated (IC0041G, 50 mg/ml), respectively as per the man-
ufacturer’s instruction. Compensation beads were used to reduce back-
ground interference (BD Bioscience, Oxford, UK). Data were collected on
an LSR2 ﬂuorescence activated cell sorter (BD Biosciences) and analysed
using the Flowjo software package (Ashland, USA). Antibodies were all pur-
chased from R&D systems (Minneapolis, MN, USA).
Statistical analysis
All statistical analysis was carried out on GraphPad Prism6 (La Jolla, CA,
USA). Data were compared using either a repeated measures ANOVA or
paired t-test (parametric). Appropriate post hoc tests were applied and sig-
niﬁcance was taken as P, 0.05. Data are presented as the mean + SEM
from at least three independent experiments.
Results
Sequence speciﬁc siRNA inhibits the
expression of DDAH1 and DDAH2 in
SGHPL-4 cells
To investigate the effect of DDAH1 and 2 dysregulation on SGHPL-4
apoptosis, we used siRNA to selectively inhibit expression. Following
24 h incubation with siRNA and a subsequent 48 h incubation in com-
plete media, DDAH1 expression was signiﬁcantly and speciﬁcally
reduced in SGHPL-4 cells at both the mRNA and protein levels, when
compared with control and the non-targeting siRNA control (Fig. 1A
and B). DDAH2 mRNA expression was also speciﬁcally inhibited as
detected byQRT–PCR butwas not detectable bywestern blot analysis.
Inhibition of DDAH1, but not DDAH2,
expression increases TRAIL-mediated
trophoblast apoptosis
To determinewhether inhibition of DDAHexpression had any effect on
TRAIL-induced SGHPL-4 cell apoptosis, cells were transfected with
control siRNA, or siRNA to either DDAH1 or 2. Cells were stimulated
with 500 ng/ml TRAIL and the induction of apoptosis was followed by
time-lapse microscopy over 24 h. There was no signiﬁcant change in
the sensitivity of SGHPL-4 cells in which the expression of DDAH2
mRNAwas inhibited. A small (but not signiﬁcant) increase in apoptosis
was seen with DDAH1 inhibition even in the absence of an exogenous
apoptotic stimulus. However, a signiﬁcant increase in apoptosis was
seen after treatmentwith TRAIL in the cells with inhibitedDDAH1 com-
pared with those with the siRNA control (Fig. 2).
ADMA increases TRAIL-induced apoptosis in
SGHPL-4 cells
SGHPL-4 cells incubated with increasing concentrations of ADMA and
then stimulated with 500 ng/ml TRAIL for 24 h underwent apoptosis
as determined by time-lapse microscopy. A dose dependent increase
in SGHPL-4 cell apoptosis was seen, reaching signiﬁcance at 100 mM
ADMA (P, 0.05) after 24 h (Fig. 3).
Figure 2 The effect of inhibiting the expression of DDAH1 and 2 on
TRAIL-induced apoptosis. Time lapse apoptosis analysis was carried out
on cells transfected with either non-targeting siRNA or siRNA targeted
to DDAH1 or 2, following addition of 500 ng/ml TRAIL for 24 h.
Twenty cells were chosen at random for each condition and induction of
apoptosis was followed by characteristic morphological changes (A). The
image on the left shows a cell prior to the onset of apoptosis, the middle
image shows the same cell rounding up and becoming bright before mem-
brane blebs and blisters develop. The image on the right shows the forma-
tion of apoptotic bodies. Kinetics curves were obtained following the
induction of apoptosis and the areas under the curve (AUC) were calcu-
lated (B). DDAH1 knockdown resulted in a signiﬁcantly increased suscep-
tibility to TRAIL-induced apoptosis. The data are shown as mean+ SEM,
from at least three independent experiments, *P, 0.05, **P, 0.01.
Figure3 The effect of ADMAonTRAIL induced apoptosis. Untrans-
fected SGHPL-4 cells were treated with ADMA at the doses indicated
and then stimulated with 500 ng/ml TRAIL for 24 h. Apoptosis was fol-
lowed by time-lapse microscopy. Adding ADMA signiﬁcantly increased
TRAIL-induced apoptosis of SGHPL-4 cells at both 100 and 200 mM
ADMA. The data shown are the mean + SEM, from at least three inde-
pendent experiments, *P, 0.05.
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Inhibition of DDAH1 increases
TRAIL-mediated apoptosis by increasing
TRAIL receptor 2 expression
Following the ﬁnding that inhibiting DDAH1 expression increased the
susceptibility to TRAIL-induced apoptosis in SGHPL-4 cells, we used
FACS to look at the expression of TRAIL receptors on the surface of
these cells. FACS analysis revealed a signiﬁcant increase in TR2 expres-
sion in those cells treated with DDAH1 targeting siRNA compared
with the non-speciﬁc siRNA (Fig. 4). Interestingly, although signiﬁcant in-
hibition was displayed with DDAH2 targeting siRNA, these did not
display the same increase in TR2 (data not shown). This could explain
why TRAIL did not induce the same increase in apoptosis in these
cells. TR1 did not display a similar increase in expression following
either DDAH1 or 2 targeting siRNA. This may indicate a speciﬁc effect
of DDAH1 on TR2 expression.
Discussion
The key ﬁndings of the present study are: (i) SGHPL-4 cells aremore sen-
sitive to TRAIL-induced apoptosis following inhibition of DDAH1 but
notDDAH2, (ii) this response could bemimickedbyexogenous addition
of ADMA an inhibitor of NO synthesis, and (iii) the increased sensitivity
was accompanied by an increase in the expression of TR2 but not TR1.
The maternal fetal interface represents a potentially hostile environ-
ment for the invading trophoblasts not least because decidual stromal
andmaternal immune cells secrete a number of pro-apoptotic cytokines
including TRAIL.Although the invading EVTs express the appropriate re-
ceptor repertoire, under normal circumstances they remain resistant to
the apoptotic actions of these cytokines. Exaggerated trophoblast apop-
tosis has been associatedwith the poor remodelling ofmaternal spiral ar-
teries seen in pregnancy complications such as PE and FGR, yet the
underlying mechanisms are poorly understood (Smith et al., 1997a;
Leung et al., 2001).
NO regulates a number of important trophoblast functions including
motility and invasion (Cartwright et al., 1999). Factors that regulate
NO synthesis can therefore have a signiﬁcant effect on establishment
of a healthy pregnancy. Primary ﬁrst trimester EVTs and the EVT cell
line SGHPL-4 used in this study express both DDAH1 and 2 mRNA
and protein (Ayling et al., 2006) and this was largely supported by the
ﬁndings of this study. We therefore sought to examine the role of
DDAH in altering sensitivity of SGHPL-4 cells to stimulation with
Figure 4 Cell surface expression of TRAIL receptor 1 and 2. The expression of TR2 by SGHPL-4 transfected with either non-targeting siRNA (A) or
siRNA targeted to DDAH1 (B) was assessed using ﬂow cytometry, the IgG control is shown in gray and the TR2 in black. TR2 is represented by the
grey line and IgG control is represented by the black line. The images shown are representative of at least three independent experiments. A comparison
of the effect of inhibiting DDAHI on the expression of both TR1 and TR2 is also shown (C). The data are shown as mean + SEM, from at least three in-
dependent experiments, *P, 0.05.
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recombinant TRAIL by independently targeting both isoforms using
siRNA. Using time-lapse microscopy, wewere unable to detect a signiﬁ-
cant change in thedegreeof apoptosis in cells transfectedwith siRNAtar-
geting DDAH2 compared with the siRNA control, however there was a
signiﬁcant difference in cells transfected with siRNA targeting DDAH1.
Although the two isoforms of DDAH are believed to have similar en-
zymatic activity, the apparent rate of ADMAmetabolism for DDAH2 is
almost 70 times less than that of DDAH1 (Pope et al., 2009). This is con-
sistent with our data indicating that only inhibition of DDAH1 affects
trophoblast apoptosis and the growing body of evidence that DDAH2
may have different biological functions (Cooke and Ghebremariam,
2011; Hu et al., 2011), as well as the demonstrated difference in tissue
and cellular distribution for the two isoforms (Chen et al., 2005). Com-
plicating the picture still further is the data suggesting that both isoforms
may regulate protein function via direct protein–protein interactions
(Tokuo et al., 2001; Hasegawa et al., 2006; Leiper and Vallance, 2006).
Therefore to determine whether the effect of inhibiting the expression
of DDAH1 on SGHPL-4 cell sensitivity to TRAIL could be mimicked
by increasing ADMA, we repeated the experiments in the presence of
exogenous ADMA and found that it too, could increase the sensitivity
of SGHPL-4 cells to stimulation by TRAIL. The data presented so far, to-
gether with our previous data on the regulation of trophoblast cell apop-
tosis, would implicate an inhibitory effect on the production of NO.We
have previously shown that NO canmodulate apoptosis in trophoblasts
through the nitrosylation of speciﬁc cysteine residues in target proteins
including protein kinase C1 and caspase 3 and 8 (Dash et al., 2003a,
2007). However a number of other mechanisms have been proposed
whichmight regulate TRAIL-induced apoptosis, including the expression
of the non-signalling decoy receptors and the redistribution of the two
death receptors to and from the cell surface. EVT express both TR1
andTR2and although activationof either receptor can lead to apoptosis,
it is believed that it is activation of TR2 that is the predominant receptor
subtype involved in the mediation of cell death in many cell types
(Schneider-Brachert et al., 2013). Inhibition of DDAH1 expression
resulted in a signiﬁcant increase in cell surface expression of TR2 and a
small but not signiﬁcant increase in the expression of TR1. A similar in-
crease in surface expression of TR2 by trophoblasts has been reported
previously in response to TNF-a (Bai et al., 2009).
In conclusion, it is known that inadequate trophoblast invasion in the
ﬁrst trimester of pregnancy is associated with poor spiral artery remod-
elling and themost severe forms of PE and FGR. Themechanisms under-
lying this failure to invade are unclear yet an understanding at a cellular or
molecular level is fundamental if we are to ameliorate or prevent these
pregnancy complications. In this study, we demonstrate a DDAH1
isoform speciﬁc effect on the sensitivity of trophoblasts to stimulation
by the apoptotic cytokineTRAIL.We further demonstrate, that exogen-
ous ADMA, the substrate for DDAH also sensitizes trophoblasts to
TRAIL. Finally we show that inhibition of DDAH1 expression is asso-
ciated with increased expression of TR2. It is therefore possible that
the increased ADMA seen in pregnancies complicated by pre-eclampsia
reﬂects amuchearlier imbalance in theDDAH/ADMAsystem leading to
the increased trophoblast apoptosis seen in this syndrome.
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